Dr. Marta New obtained a degree in Immunology and Microbiology from the University of Illinois at Chicago (2006) and completed a postdoctoral fellowship at Northwestern University (2009). She then obtained an MBA in Finance and Marketing at Kellogg School of Management in Chicago (2011). Dr. New has extensive experience in venture capital investments and continues to translate that experience into tangible solutions for clients in need of strategic product development, fundraising, and commercialization of preclinical therapeutics.
Dr. Marta New is the founder and CEO of Radyus Research. As an experienced drug developer with a background in early-stage venture capital, large pharma R&D, and university technology transfer, she brings invaluable business acumen and extensive international connections to Radyus. Dr. New’s previous roles as partner at Agent Capital, principal investor at Baxalta Ventures, commercial lead at Baxter International’s renal franchise, and entrepreneur in residence at Northwestern University have helped her establish the foundation for the work done at Radyus.
At Agent Capital, Dr. New participated in multiple venture capital investments in oncology, immunology, and rare disease areas, including Pliant Therapeutics (NASDAQ:PLRX), Orchard Therapeutics (NASDAQ:ORTX), and Verge Genomics. At Baxalta Ventures, the corporate venture capital arm of Baxalta in Cambridge, MA, Dr. New participated in multiple venture capital investments and served as a board observer for Gadeta BV, Syntimmune, and Vitesse Biologics (early-stage accelerator funded by Baxalta, Mayo Clinic, and Velocity Pharmaceutical Development). At Northwestern University’s technology transfer office, Dr. New served as an entrepreneur in residence and facilitated formation of several biotech spinout companies in the oncology and CNS space.
Dr. New received her PhD in Immunology and Microbiology from the University of Illinois at Chicago and completed a postdoctoral fellowship at Northwestern University. She then earned an MBA in Finance and Marketing at Kellogg School of Management in Chicago.
Dr. New spent most of her career translating early academic research into differentiated therapeutics and draws her expertise from positions at Baxter, Baxalta Ventures, Agent Capital, and Northwestern’s technology transfer. Additionally, she has participated in building several successful academic spinouts and invested in over 20 biotech companies.
Dr. New aims to advise Radyus clients regarding strategies for successful product development, fundraising, and commercialization.
The rich text element allows you to create and format headings, paragraphs, blockquotes, images, and video all in one place instead of having to add and format them individually. Just double-click and easily create content.
A rich text element can be used with static or dynamic content. For static content, just drop it into any page and begin editing. For dynamic content, add a rich text field to any collection and then connect a rich text element to that field in the settings panel. Voila!
Headings, paragraphs, blockquotes, figures, images, and figure captions can all be styled after a class is added to the rich text element using the "When inside of" nested selector system.
The rich text element allows you to create and format headings, paragraphs, blockquotes, images, and video all in one place instead of having to add and format them individually. Just double-click and easily create content.
A rich text element can be used with static or dynamic content. For static content, just drop it into any page and begin editing. For dynamic content, add a rich text field to any collection and then connect a rich text element to that field in the settings panel. Voila!
Headings, paragraphs, blockquotes, figures, images, and figure captions can all be styled after a class is added to the rich text element using the "When inside of" nested selector system.
I find it deeply rewarding to help navigate effective product development, fundraising, and commercialization strategies for our clients. I want to see their experiments lead to something meaningful. --Dr. Marta New
